<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Expression Based RAS Pathway Predicts CRC Cetuximab Response

Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC), excluding patients with KRAS codon 12/13 mutations. However, several reports have suggested that these criteria alone are not optimal for stratifying mCRC patients.